Other Sales was Nanobiotix’s largest revenue line in fiscal 2024, bringing in $5.90M of $11.70M (50%).
| Products and services [axis] | FY 2024 |
|---|---|
| Other Sales | $5.90M |
| Research & Development | $4.00M |
| Technology Transfer | $1.80M |
| Total | $11.70M |
Nanobiotix brought in $11.70M from its three revenue lines in fiscal 2024, the year ended December 31, 2024. Other Sales was the largest at $5.90M (50.4%), ahead of Research & Development at $4.00M (34.2%) and Technology Transfer at $1.80M (15.4%).
Nanobiotix (NBTX) reports its revenue by products and services [axis]. In fiscal 2024, Other Sales was its largest revenue line, bringing in $5.90M (50.4% of the total), followed by Research & Development at $4.00M (34.2%).
Other Sales was Nanobiotix's largest revenue line in fiscal 2024, bringing in $5.90M, or 50.4% of the $11.70M total across its three revenue lines.
Every figure comes from Nanobiotix's annual financial filings, as reported. Each line keeps the name Nanobiotix gives it, and years follow its fiscal calendar.
Nanobiotix's revenue by products and services [axis] goes back to fiscal 2024, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.